» Articles » PMID: 23017617

Cut Points on 0-10 Numeric Rating Scales for Symptoms Included in the Edmonton Symptom Assessment Scale in Cancer Patients: a Systematic Review

Overview
Publisher Elsevier
Date 2012 Sep 29
PMID 23017617
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Context: To improve the management of cancer-related symptoms, systematic screening is necessary, often performed by using 0-10 numeric rating scales. Cut points are used to determine if scores represent clinically relevant burden.

Objectives: The aim of this systematic review was to explore the evidence on cut points for the symptoms of the Edmonton Symptom Assessment Scale.

Methods: Relevant literature was searched in PubMed, CINAHL®, Embase, and PsycINFO®. We defined a cut point as the lower bound of the scores representing moderate or severe burden.

Results: Eighteen articles were eligible for this review. Cut points were determined using the interference with daily life, another symptom-related method, or a verbal scale. For pain, cut point 5 and, to a lesser extent, cut point 7 were found as the optimal cut points for moderate pain and severe pain, respectively. For moderate tiredness, the best cut point seemed to be cut point 4. For severe tiredness, both cut points 7 and 8 were suggested frequently. A lack of evidence exists for nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath. Few studies suggested a cut point below 4.

Conclusion: For many symptoms, there is no clear evidence as to what the optimal cut points are. In daily clinical practice, a symptom score ≥4 is recommended as a trigger for a more comprehensive symptom assessment. Until there is more evidence on the optimal cut points, we should hold back using a certain cut point in quality indicators and be cautious about strongly recommending a certain cut point in guidelines.

Citing Articles

Symptoms, Symptom Profiles, and Healthcare Utilization in Patients with Hematologic Malignancies: A Retrospective Observational Cohort Study and Latent Class Analysis.

Booker R, Sawatzky R, Sinnarajah A, Qi S, Link C, Watson L Curr Oncol. 2025; 32(2).

PMID: 39996862 PMC: 11854205. DOI: 10.3390/curroncol32020062.


Prevalence of anhedonia in women with deep endometriosis.

Mallorqui A, Fortuna A, Segura E, Cardona G, Espinosa M, Quintas-Marques L Sci Rep. 2025; 15(1):752.

PMID: 39755741 PMC: 11700138. DOI: 10.1038/s41598-024-84772-8.


Health Resort Treatment Improves Functioning and Physical Performance in Long COVID Patients: A Retrospective Study.

Onik G, Knapik K, Dabrowska-Galas M, Sieron K Healthcare (Basel). 2024; 12(23).

PMID: 39684966 PMC: 11640831. DOI: 10.3390/healthcare12232344.


AI-Driven Prediction of Symptom Trajectories in Cancer Care: A Deep Learning Approach for Chemotherapy Management.

Finkelstein J, Smiley A, Echeverria C, Mooney K Bioengineering (Basel). 2024; 11(11).

PMID: 39593830 PMC: 11592055. DOI: 10.3390/bioengineering11111172.


Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy.

Koldenhof J, Akpobome B, Zweers D, Klaasse S, Teunissen S, Witteveen P J Patient Rep Outcomes. 2024; 8(1):120.

PMID: 39422800 PMC: 11489364. DOI: 10.1186/s41687-024-00794-w.